SMN-C3

• Description:

  SMN-C3 is an orally active SMN2 splicing modulator and has the potential to treat spinal muscular atrophy (SMA) .

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H320

• Target:

  DNA/RNA Synthesis

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Field of Research:

  Others

• Assay Protocol:

  https://www.medchemexpress.com/SMN-C3.html

• Purity:

  99.53

• Solubility:

  DMSO : 1.96 mg/mL (ultrasonic; warming; adjust pH to 5 with HCl; heat to 60°C)

• Smiles:

  O=C1C=C(C2=NN3C(C(C)=NC(C)=C3)=C2)N=C4N1C=C(C5CCN(CC)CC5)C=C4C

• Molecular Formula:

  C24H28N6O

• Molecular Weight:

  416.52

• Precautions:

  H315, H319, H320

• References & Citations:

  [1]Naryshkin NA, et al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science. 2014 Aug 8;345 (6197) :688-93.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1449597-34-5]